Proteome alterations in pancreatic ductal adenocarcinoma

被引:20
|
作者
Pan, Sheng [1 ]
Brentnall, Teresa A. [2 ]
Chen, Ru [3 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX 77030 USA
[2] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA
[3] Baylor Coll Med, Dept Med, Div Gastroenterol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
Pancreatic cancer; Proteomics; Mass spectrometry; Post-translational modification; Glycosylation; POSTTRANSLATIONAL MODIFICATIONS; GALECTIN-1; EXPRESSION; CANCER PROGRESSION; ANALYSIS REVEALS; PROTEINS; GLYCOSYLATION; MICROENVIRONMENT; DIAGNOSIS; BIOMARKER; GLYCOPROTEOMICS;
D O I
10.1016/j.canlet.2019.11.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteins are the essential functional biomolecules profoundly implicated in all aspects of pancreatic tumorigenesis and its progression. While common genomic factors, such as KRAS, TP53, SMAD4, and CDKN2A have been well recognized in association of pancreatic ductal adenocarcinoma (PDAC), our understanding of functional changes at the proteome level merits further investigation. Malignance associated proteome alterations can be attributed to the convoluted outcomes from genetic, epigenetic and environmental factors in initiating and progressing PDAC, and may reflect on changes in protein expressional level, structure, localization, as well as post-translational modifications (PTMs) status. The study of localized or systemic proteome alterations in PDAC, as well as its precursor lesions, such as pancreatic intraepithelial neoplasia (PanIN) and mucinous pancreatic cystic neoplasm, would provide unique perspectives in elucidating functional molecular events underlying PDAC. While efforts have been made, challenges still exist to comprehensively integrate much of the proteomic discovery to the perspectives gained from genomic studies in the context of biomarker discovery. Novel approaches and data from well-defined longitudinal clinical studies and experimental models are needed to facilitate the study of PDAC and precursor lesions for early detection and intervention.
引用
收藏
页码:429 / 436
页数:8
相关论文
共 50 条
  • [31] Macrophages and pancreatic ductal adenocarcinoma
    Habtezion, Aida
    Edderkaoui, Mouad
    Pandol, Stephen J.
    CANCER LETTERS, 2016, 381 (01) : 211 - 216
  • [32] Staging of pancreatic ductal adenocarcinoma
    Sauvanet, A
    Zins, M
    JOURNAL DE CHIRURGIE, 1998, 135 (01): : 10 - 16
  • [33] FOLFIRINOX for Pancreatic Ductal Adenocarcinoma
    Alakus, Hakan
    Korenkov, Michael
    Kuetting, Fabian
    Bruns, Christiane
    ONKOLOGE, 2019, 25 (08): : 726 - 727
  • [34] Immunotherapy for pancreatic ductal adenocarcinoma
    Carpenter, Eileen
    Nelson, Sarah
    Bednar, Filip
    Cho, Clifford
    Nathan, Hari
    Sahai, Vaibhav
    di Magliano, Marina Pasca
    Frankel, Timothy L.
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 123 (03) : 751 - 759
  • [35] Biomarkers in pancreatic ductal adenocarcinoma
    Gallego, J.
    Lopez, C.
    Pazo-Cid, R.
    Lopez-Rios, F.
    Carrato, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (12): : 1430 - 1437
  • [36] Desmoplasia of Pancreatic Ductal Adenocarcinoma
    Pandol, Stephen
    Edderkaoui, Mouad
    Gukovsky, Ilya
    Lugea, Aurelia
    Gukovskaya, Anna
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (11) : S44 - S47
  • [37] Models of pancreatic ductal adenocarcinoma
    Rayane Dennaoui
    Hridaya Shrestha
    Kay-Uwe Wagner
    Cancer and Metastasis Reviews, 2021, 40 : 803 - 818
  • [38] Carcinogenesis of Pancreatic Ductal Adenocarcinoma
    Storz, Peter
    Crawford, Howard C.
    GASTROENTEROLOGY, 2020, 158 (08) : 2072 - 2081
  • [39] Genomics of pancreatic ductal adenocarcinoma
    Pilarsky, Christian
    Gruetzmann, Robert
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2014, 13 (04) : 381 - 385
  • [40] Genomics of pancreatic ductal adenocarcinoma
    Christian Pilarsky
    Robert Grützmann
    Hepatobiliary & Pancreatic Diseases International, 2014, 13 (04) : 381 - 385